{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T13:37:46Z","timestamp":1776433066258,"version":"3.51.2"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,24]],"date-time":"2024-10-24T00:00:00Z","timestamp":1729728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,10,24]],"date-time":"2024-10-24T00:00:00Z","timestamp":1729728000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"International Science and Technology Cooperation promotion program of Shihezi university","award":["GJHZ202301"],"award-info":[{"award-number":["GJHZ202301"]}]},{"name":"Strong Youth Science and Technology Leading Talents in Science and Technology Innovation project of Corps","award":["2023CB008-02"],"award-info":[{"award-number":["2023CB008-02"]}]},{"DOI":"10.13039\/501100001809","name":"The National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82360494"],"award-info":[{"award-number":["82360494"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-76945-2","type":"journal-article","created":{"date-parts":[[2024,10,24]],"date-time":"2024-10-24T15:03:39Z","timestamp":1729782219000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Ubiquitin-related gene markers predict immunotherapy response and prognosis in patients with epithelial ovarian carcinoma"],"prefix":"10.1038","volume":"14","author":[{"given":"Donglin","family":"Luo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoning","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yankun","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yeernaer","family":"Hazaisihan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Tao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siyuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Jia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,10,24]]},"reference":[{"issue":"1","key":"76945_CR1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel, R. L., Miller, K. D., Wagle, N. S. & Jemal, A. Cancer statistics, 2023. CA Cancer J. Clin. 73 (1), 17\u201348 (2023).","journal-title":"CA Cancer J. Clin."},{"issue":"1","key":"76945_CR2","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s13048-019-0484-6","volume":"12","author":"A Gadducci","year":"2019","unstructured":"Gadducci, A. et al. Current strategies for the targeted treatment of high-grade serous epithelial ovarian cancer and relevance of BRCA mutational status. J. Ovarian Res. 12 (1), 9 (2019).","journal-title":"J. Ovarian Res."},{"issue":"1","key":"76945_CR3","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s12943-020-1130-z","volume":"19","author":"S Munoz-Galvan","year":"2020","unstructured":"Munoz-Galvan, S. et al. Downregulation of MYPT1 increases tumor resistance in ovarian cancer by targeting the Hippo pathway and increasing the stemness. Mol. Cancer. 19 (1), 7 (2020).","journal-title":"Mol. Cancer"},{"issue":"7","key":"76945_CR4","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1038\/s41388-019-1087-9","volume":"39","author":"M Asare-Werehene","year":"2020","unstructured":"Asare-Werehene, M. et al. The exosome-mediated autocrine and paracrine actions of plasma gelsolin in ovarian cancer chemoresistance. Oncogene. 39 (7), 1600\u20131616 (2020).","journal-title":"Oncogene"},{"key":"76945_CR5","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1146\/annurev.pharmtox.051208.165340","volume":"49","author":"AL Schwartz","year":"2009","unstructured":"Schwartz, A. L. & Ciechanover, A. Targeting proteins for destruction by the ubiquitin system: implications for human pathobiology. Annu. Rev. Pharmacol. Toxicol. 49, 73\u201396 (2009).","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"76945_CR6","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1042\/bse0410187","volume":"41","author":"A Devoy","year":"2005","unstructured":"Devoy, A., Soane, T., Welchman, R. & Mayer, R. J. The ubiquitin-proteasome system and cancer. Essays Biochem. 41, 187\u2013203 (2005).","journal-title":"Essays Biochem."},{"issue":"5","key":"76945_CR7","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1091\/mbc.E17-10-0589","volume":"29","author":"CM Hickey","year":"2018","unstructured":"Hickey, C. M., Xie, Y. & Hochstrasser, M. DNA binding by the MATalpha2 transcription factor controls its access to alternative ubiquitin-modification pathways. Mol. Biol. Cell. 29 (5), 542\u2013556 (2018).","journal-title":"Mol. Biol. Cell."},{"issue":"3","key":"76945_CR8","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/S0092-8674(00)80929-0","volume":"92","author":"W Baumeister","year":"1998","unstructured":"Baumeister, W., Walz, J., Zuhl, F. & Seemuller, E. The proteasome: paradigm of a self-compartmentalizing protease. Cell. 92 (3), 367\u2013380 (1998).","journal-title":"Cell"},{"issue":"7237","key":"76945_CR9","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/458421a","volume":"458","author":"D Nath","year":"2009","unstructured":"Nath, D. & Shadan, S. The ubiquitin system. Nature. 458 (7237), 421 (2009).","journal-title":"Nature"},{"issue":"6","key":"76945_CR10","doi-asserted-by":"publisher","first-page":"324","DOI":"10.3747\/co.19.1175","volume":"19","author":"Z Rao","year":"2012","unstructured":"Rao, Z. & Ding, Y. Ubiquitin pathway and ovarian cancer. Curr. Oncol. 19 (6), 324\u2013328 (2012).","journal-title":"Curr. Oncol."},{"issue":"1","key":"76945_CR11","doi-asserted-by":"publisher","first-page":"6298","DOI":"10.1038\/s41467-020-20140-0","volume":"11","author":"M Song","year":"2020","unstructured":"Song, M. et al. Tumor derived UBR5 promotes ovarian cancer growth and metastasis through inducing immunosuppressive macrophages. Nat. Commun. 11 (1), 6298 (2020).","journal-title":"Nat. Commun."},{"issue":"7","key":"76945_CR12","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1016\/j.ccell.2021.04.004","volume":"39","author":"M Hornburg","year":"2021","unstructured":"Hornburg, M. et al. Single-cell dissection of cellular components and interactions shaping the tumor immune phenotypes in ovarian cancer. Cancer Cell. 39 (7), 928\u2013944e926 (2021).","journal-title":"Cancer Cell."},{"issue":"2","key":"76945_CR13","doi-asserted-by":"publisher","first-page":"188361","DOI":"10.1016\/j.bbcan.2020.188361","volume":"1873","author":"Y Jiang","year":"2020","unstructured":"Jiang, Y., Wang, C. & Zhou, S. Targeting tumor microenvironment in ovarian cancer: Premise and promise. Biochim. Biophys. Acta Rev. Cancer. 1873 (2), 188361 (2020).","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"issue":"5","key":"76945_CR14","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1111\/j.1440-1827.2009.02369.x","volume":"59","author":"K Kawamura","year":"2009","unstructured":"Kawamura, K., Komohara, Y., Takaishi, K., Katabuchi, H. & Takeya, M. Detection of M2 macrophages and colony-stimulating factor 1 expression in serous and mucinous ovarian epithelial tumors. Pathol. Int. 59 (5), 300\u2013305 (2009).","journal-title":"Pathol. Int."},{"issue":"16","key":"76945_CR15","doi-asserted-by":"publisher","first-page":"3590","DOI":"10.1158\/1078-0432.CCR-22-0296","volume":"28","author":"J Xu","year":"2022","unstructured":"Xu, J. et al. Single-cell RNA sequencing reveals the tissue Architecture in Human High-Grade Serous Ovarian Cancer. Clin. Cancer Res. 28 (16), 3590\u20133602 (2022).","journal-title":"Clin. Cancer Res."},{"issue":"12","key":"76945_CR16","doi-asserted-by":"publisher","first-page":"300060521106624","DOI":"10.1177\/03000605211066245","volume":"49","author":"T Zhang","year":"2021","unstructured":"Zhang, T. et al. Lymphocyte and macrophage infiltration in omental metastases indicates poor prognosis in advance stage epithelial ovarian cancer. J. Int. Med. Res. 49 (12), 3000605211066245 (2021).","journal-title":"J. Int. Med. Res."},{"issue":"1","key":"76945_CR17","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.ygyno.2015.01.539","volume":"137","author":"AE Wahner Hendrickson","year":"2015","unstructured":"Wahner Hendrickson, A. E. et al. Assessment of published models and prognostic variables in epithelial ovarian cancer at Mayo Clinic. Gynecol. Oncol. 137 (1), 77\u201385 (2015).","journal-title":"Gynecol. Oncol."},{"issue":"19","key":"76945_CR18","doi-asserted-by":"publisher","first-page":"5937","DOI":"10.1158\/1078-0432.CCR-18-3720","volume":"25","author":"C Bodelon","year":"2019","unstructured":"Bodelon, C. et al. Molecular classification of epithelial ovarian Cancer based on methylation profiling: evidence for Survival Heterogeneity. Clin. Cancer Res. 25 (19), 5937\u20135946 (2019).","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"76945_CR19","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/nar\/28.1.27","volume":"28","author":"M Kanehisa","year":"2000","unstructured":"Kanehisa, M. & Goto, S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 28 (1), 27\u201330 (2000).","journal-title":"Nucleic Acids Res."},{"issue":"11","key":"76945_CR20","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1002\/pro.3715","volume":"28","author":"M Kanehisa","year":"2019","unstructured":"Kanehisa, M. Toward understanding the origin and evolution of cellular organisms. Protein Sci. 28 (11), 1947\u20131951 (2019).","journal-title":"Protein Sci."},{"issue":"D1","key":"76945_CR21","doi-asserted-by":"publisher","first-page":"D587","DOI":"10.1093\/nar\/gkac963","volume":"51","author":"M Kanehisa","year":"2023","unstructured":"Kanehisa, M., Furumichi, M., Sato, Y., Kawashima, M. & Ishiguro-Watanabe, M. KEGG for taxonomy-based analysis of pathways and genomes. Nucleic Acids Res. 51 (D1), D587\u2013d592 (2023).","journal-title":"Nucleic Acids Res."},{"issue":"1389","key":"76945_CR22","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1098\/rstb.1999.0494","volume":"354","author":"P Zwickl","year":"1999","unstructured":"Zwickl, P., Voges, D. & Baumeister, W. The proteasome: a macromolecular assembly designed for controlled proteolysis. Philos. Trans. R Soc. Lond. B Biol. Sci. 354 (1389), 1501\u20131511 (1999).","journal-title":"Philos. Trans. R Soc. Lond. B Biol. Sci."},{"key":"76945_CR23","doi-asserted-by":"publisher","first-page":"684643","DOI":"10.3389\/fcell.2021.684643","volume":"9","author":"Y Wu","year":"2021","unstructured":"Wu, Y. et al. Development of an Individualized Ubiquitin Prognostic signature for Clear Cell Renal Cell Carcinoma. Front. Cell. Dev. Biol. 9, 684643 (2021).","journal-title":"Front. Cell. Dev. Biol."},{"key":"76945_CR24","doi-asserted-by":"crossref","unstructured":"Chen, X. et al. Development of an ubiquitin-proteasome system signature for predicting prognosis and providing therapeutic guidance for patients with triple-negative breast cancer. J. Gene Med. 26(1):e3584. (2023).","DOI":"10.1002\/jgm.3584"},{"key":"76945_CR25","doi-asserted-by":"publisher","first-page":"629327","DOI":"10.3389\/fonc.2021.629327","volume":"11","author":"W Ni","year":"2021","unstructured":"Ni, W. et al. Identification and validation of Ubiquitin-Specific proteases as a Novel Prognostic signature for Hepatocellular Carcinoma. Front. Oncol. 11, 629327 (2021).","journal-title":"Front. Oncol."},{"key":"76945_CR26","doi-asserted-by":"publisher","first-page":"778503","DOI":"10.3389\/fgene.2021.778503","volume":"12","author":"G Song","year":"2021","unstructured":"Song, G. et al. Identification of a Ubiquitin related genes signature for Predicting prognosis of prostate Cancer. Front. Genet. 12, 778503 (2021).","journal-title":"Front. Genet."},{"issue":"2 Pt 1","key":"76945_CR27","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.gene.2015.08.063","volume":"575","author":"M Haase","year":"2016","unstructured":"Haase, M. & Fitze, G. HSP90AB1: helping the good and the bad. Gene. 575 (2 Pt 1), 171\u2013186 (2016).","journal-title":"Gene"},{"issue":"10","key":"76945_CR28","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1007\/s10815-018-1263-9","volume":"35","author":"DA Nikishin","year":"2018","unstructured":"Nikishin, D. A. et al. Selection of stable expressed reference genes in native and vitrified\/thawed human ovarian tissue for analysis by qRT-PCR and Western blot. J. Assist. Reprod. Genet. 35 (10), 1851\u20131860 (2018).","journal-title":"J. Assist. Reprod. Genet."},{"issue":"2","key":"76945_CR29","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1007\/s11033-021-07057-7","volume":"49","author":"S Hussain","year":"2022","unstructured":"Hussain, S. et al. F-box only protein 9 and its role in cancer. Mol. Biol. Rep. 49 (2), 1537\u20131544 (2022).","journal-title":"Mol. Biol. Rep."},{"issue":"3","key":"76945_CR30","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1038\/bjc.1993.101","volume":"67","author":"WD Foulkes","year":"1993","unstructured":"Foulkes, W. D., Ragoussis, J., Stamp, G. W., Allan, G. J. & Trowsdale, J. Frequent loss of heterozygosity on chromosome 6 in human ovarian carcinoma. Br. J. Cancer. 67 (3), 551\u2013559 (1993).","journal-title":"Br. J. Cancer"},{"issue":"3","key":"76945_CR31","first-page":"1405","volume":"39","author":"Q Xu","year":"2018","unstructured":"Xu, Q. et al. Sigma-1 receptor (\u03c31R) is downregulated in hepatic malignant tumors and regulates HepG2 cell proliferation, migration and apoptosis. Oncol. Rep. 39 (3), 1405\u20131413 (2018).","journal-title":"Oncol. Rep."},{"issue":"7","key":"76945_CR32","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1038\/bjc.2015.81","volume":"112","author":"M Koti","year":"2015","unstructured":"Koti, M. et al. A distinct pre-existing inflammatory tumour microenvironment is associated with chemotherapy resistance in high-grade serous epithelial ovarian cancer. Br. J. Cancer. 112 (7), 1215\u20131222 (2015).","journal-title":"Br. J. Cancer"},{"issue":"4","key":"76945_CR33","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1002\/cjp2.55","volume":"2","author":"KK Au","year":"2016","unstructured":"Au, K. K. et al. STAT1-associated intratumoural T(H)1 immunity predicts chemotherapy resistance in high-grade serous ovarian cancer. J. Pathol. Clin. Res. 2 (4), 259\u2013270 (2016).","journal-title":"J. Pathol. Clin. Res."},{"issue":"3","key":"76945_CR34","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1097\/IGC.0000000000001193","volume":"28","author":"JA Josahkian","year":"2018","unstructured":"Josahkian, J. A. et al. Increased STAT1 expression in high Grade Serous Ovarian Cancer is Associated with a better outcome. Int. J. Gynecol. Cancer. 28 (3), 459\u2013465 (2018).","journal-title":"Int. J. Gynecol. Cancer"},{"key":"76945_CR35","doi-asserted-by":"publisher","first-page":"636595","DOI":"10.3389\/fcell.2021.636595","volume":"9","author":"X Li","year":"2021","unstructured":"Li, X., Wang, F., Xu, X., Zhang, J. & Xu, G. The dual role of STAT1 in Ovarian Cancer: insight into Molecular mechanisms and Application potentials. Front. Cell. Dev. Biol. 9, 636595 (2021).","journal-title":"Front. Cell. Dev. Biol."},{"issue":"4","key":"76945_CR36","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1158\/1078-0432.CCR-14-1860","volume":"21","author":"GL Beatty","year":"2015","unstructured":"Beatty, G. L. & Gladney, W. L. Immune escape mechanisms as a guide for cancer immunotherapy. Clin. Cancer Res. 21 (4), 687\u2013692 (2015).","journal-title":"Clin. Cancer Res."},{"key":"76945_CR37","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.cyto.2015.11.011","volume":"89","author":"K Meissl","year":"2017","unstructured":"Meissl, K., Macho-Maschler, S., M\u00fcller, M. & Strobl, B. The good and the bad faces of STAT1 in solid tumours. Cytokine. 89, 12\u201320 (2017).","journal-title":"Cytokine"},{"key":"76945_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.intimp.2019.02.007","volume":"70","author":"Y Jin","year":"2019","unstructured":"Jin, Y. et al. IL-21 reinvigorates exhausted natural killer cells in patients with HBV-associated hepatocellular carcinoma in STAT1-depedent pathway. Int. Immunopharmacol. 70, 1\u20138 (2019).","journal-title":"Int. Immunopharmacol."},{"key":"76945_CR39","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1186\/1471-2407-9-368","volume":"9","author":"L Osterberg","year":"2009","unstructured":"Osterberg, L. et al. Potential predictive markers of chemotherapy resistance in stage III ovarian serous carcinomas. BMC Cancer. 9, 368 (2009).","journal-title":"BMC Cancer"},{"key":"76945_CR40","doi-asserted-by":"crossref","unstructured":"Menyh\u00e1rt, O., Fekete, J. T. & Gy\u0151rffy, B. Gene expression indicates altered Immune Modulation and Signaling Pathway Activation in Ovarian Cancer patients resistant to Topotecan. Int. J. Mol. Sci. 20(11), 2750 (2019).","DOI":"10.3390\/ijms20112750"},{"issue":"1","key":"76945_CR41","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1186\/s12943-019-1080-5","volume":"18","author":"L Zhang","year":"2019","unstructured":"Zhang, L. et al. CircPLEKHM3 acts as a tumor suppressor through regulation of the miR-9\/BRCA1\/DNAJB6\/KLF4\/AKT1 axis in ovarian cancer. Mol. Cancer. 18 (1), 144 (2019).","journal-title":"Mol. Cancer"},{"issue":"5\u20136","key":"76945_CR42","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1615\/CritRevOncog.2018027913","volume":"23","author":"T Huang","year":"2018","unstructured":"Huang, T. et al. Autophagy and Hallmarks of Cancer. Crit. Rev. Oncog. 23 (5\u20136), 247\u2013267 (2018).","journal-title":"Crit. Rev. Oncog."},{"issue":"1","key":"76945_CR43","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1038\/s41467-019-09800-y","volume":"10","author":"G Segala","year":"2019","unstructured":"Segala, G. et al. Vps11 and Vps18 of Vps-C membrane traffic complexes are E3 ubiquitin ligases and fine-tune signalling. Nat. Commun. 10 (1), 1833 (2019).","journal-title":"Nat. Commun."},{"key":"76945_CR44","doi-asserted-by":"crossref","unstructured":"D\u2019Arca, D. et al. Serum Mass Spectrometry Proteomics and Protein Set Identification in response to FOLFOX-4 in drug-resistant ovarian carcinoma. Cancers (Basel) 15(2), 412 (2023).","DOI":"10.3390\/cancers15020412"},{"issue":"9","key":"76945_CR45","doi-asserted-by":"publisher","first-page":"12929","DOI":"10.18632\/aging.202964","volume":"13","author":"YR Lin","year":"2021","unstructured":"Lin, Y. R., Yang, W. J. & Yang, G. W. Prognostic and immunological potential of PPM1G in hepatocellular carcinoma. Aging (Albany NY). 13 (9), 12929\u201312954 (2021).","journal-title":"Aging (Albany NY)"},{"issue":"7","key":"76945_CR46","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1038\/s41418-018-0231-3","volume":"26","author":"C Di","year":"2019","unstructured":"Di, C. et al. Function, clinical application, and strategies of Pre-mRNA splicing in cancer. Cell. Death Differ. 26 (7), 1181\u20131194 (2019).","journal-title":"Cell. Death Differ."},{"issue":"9","key":"76945_CR47","doi-asserted-by":"publisher","first-page":"e106733","DOI":"10.1371\/journal.pone.0106733","volume":"9","author":"MY Radeva","year":"2014","unstructured":"Radeva, M. Y., Kugelmann, D., Spindler, V. & Waschke, J. PKA compartmentalization via AKAP220 and AKAP12 contributes to endothelial barrier regulation. PLoS One. 9 (9), e106733 (2014).","journal-title":"PLoS One"},{"key":"76945_CR48","doi-asserted-by":"publisher","first-page":"943006","DOI":"10.3389\/fgene.2022.943006","volume":"13","author":"Q Liang","year":"2022","unstructured":"Liang, Q. et al. Pan-cancer analysis of the prognosis and immunological role of AKAP12: a potential biomarker for resistance to anti-VEGF inhibitors. Front. Genet. 13, 943006 (2022).","journal-title":"Front. Genet."},{"issue":"2","key":"76945_CR49","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s10555-016-9623-3","volume":"35","author":"RK Goel","year":"2016","unstructured":"Goel, R. K. & Lukong, K. E. Understanding the cellular roles of fyn-related kinase (FRK): implications in cancer biology. Cancer Metastasis Rev. 35 (2), 179\u2013199 (2016).","journal-title":"Cancer Metastasis Rev."},{"issue":"17","key":"76945_CR50","doi-asserted-by":"publisher","first-page":"2728","DOI":"10.4161\/cc.8.17.9389","volume":"8","author":"PM Brauer","year":"2009","unstructured":"Brauer, P. M. & Tyner, A. L. RAKing in AKT: a tumor suppressor function for the intracellular tyrosine kinase FRK. Cell. Cycle. 8 (17), 2728\u20132732 (2009).","journal-title":"Cell. Cycle"},{"issue":"4","key":"76945_CR51","doi-asserted-by":"publisher","first-page":"751","DOI":"10.4149\/neo_2021_201128N1285","volume":"68","author":"XZ Yu","year":"2021","unstructured":"Yu, X. Z. et al. TRIM44 facilitates ovarian cancer proliferation, migration, and invasion by inhibiting FRK. Neoplasma. 68 (4), 751\u2013759 (2021).","journal-title":"Neoplasma"},{"issue":"9","key":"76945_CR52","doi-asserted-by":"publisher","first-page":"e0220973","DOI":"10.1371\/journal.pone.0220973","volume":"14","author":"MA Altemus","year":"2019","unstructured":"Altemus, M. A. et al. Breast cancers utilize hypoxic glycogen stores via PYGB, the brain isoform of glycogen phosphorylase, to promote metastatic phenotypes. PLoS One. 14 (9), e0220973 (2019).","journal-title":"PLoS One"},{"issue":"4","key":"76945_CR53","first-page":"3800","volume":"18","author":"Z Wang","year":"2018","unstructured":"Wang, Z., Han, G., Liu, Q., Zhang, W. & Wang, J. Silencing of PYGB suppresses growth and promotes the apoptosis of prostate cancer cells via the NF\u2013\u03baB\/Nrf2 signaling pathway. Mol. Med. Rep. 18 (4), 3800\u20133808 (2018).","journal-title":"Mol. Med. Rep."},{"issue":"11","key":"76945_CR54","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1054\/bjoc.2001.1824","volume":"84","author":"S Shimada","year":"2001","unstructured":"Shimada, S., Shiomori, K., Tashima, S., Tsuruta, J. & Ogawa, M. Frequent p53 mutation in brain (fetal)-type glycogen phosphorylase positive foci adjacent to human \u2018de novo\u2019 colorectal carcinomas. Br. J. Cancer. 84 (11), 1497\u20131504 (2001).","journal-title":"Br. J. Cancer"},{"issue":"1","key":"76945_CR55","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1111\/j.1572-0241.2000.01692.x","volume":"95","author":"S Tashima","year":"2000","unstructured":"Tashima, S., Shimada, S., Yamaguchi, K., Tsuruta, J. & Ogawa, M. Expression of brain-type glycogen phosphorylase is a potentially novel early biomarker in the carcinogenesis of human colorectal carcinomas. Am. J. Gastroenterol. 95 (1), 255\u2013263 (2000).","journal-title":"Am. J. Gastroenterol."},{"issue":"10","key":"76945_CR56","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1111\/j.1349-7006.1989.tb01636.x","volume":"80","author":"M Takashi","year":"1989","unstructured":"Takashi, M., Koshikawa, T., Kurobe, N. & Kato, K. Elevated concentrations of brain-type glycogen phosphorylase in renal cell carcinoma. Jpn J. Cancer Res. 80 (10), 975\u2013980 (1989).","journal-title":"Jpn J. Cancer Res."},{"issue":"1","key":"76945_CR57","first-page":"111","volume":"18","author":"S Shimada","year":"1999","unstructured":"Shimada, S., Tashima, S., Yamaguchi, K., Matsuzaki, H. & Ogawa, M. Carcinogenesis of intestinal-type gastric cancer and colorectal cancer is commonly accompanied by expression of brain (fetal)-type glycogen phosphorylase. J. Exp. Clin. Cancer Res. 18 (1), 111\u2013118 (1999).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"76945_CR58","doi-asserted-by":"publisher","first-page":"109449","DOI":"10.1016\/j.biopha.2019.109449","volume":"120","author":"Y Zhou","year":"2019","unstructured":"Zhou, Y., Jin, Z. & Wang, C. Glycogen phosphorylase B promotes ovarian cancer progression via Wnt\/\u03b2-catenin signaling and is regulated by miR-133a-3p. Biomed. Pharmacother. 120, 109449 (2019).","journal-title":"Biomed. Pharmacother"},{"issue":"4","key":"76945_CR59","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1007\/s10147-017-1145-7","volume":"22","author":"J Murai","year":"2017","unstructured":"Murai, J. Targeting DNA repair and replication stress in the treatment of ovarian cancer. Int. J. Clin. Oncol. 22 (4), 619\u2013628 (2017).","journal-title":"Int. J. Clin. Oncol."},{"key":"76945_CR60","doi-asserted-by":"crossref","unstructured":"Nayak, A. P., Kapur, A., Barroilhet, L. & Patankar, M. S. Oxidative phosphorylation: a target for Novel therapeutic strategies against ovarian Cancer. Cancers (Basel) 10(9), 337 (2018).","DOI":"10.3390\/cancers10090337"},{"issue":"9","key":"76945_CR61","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.7150\/jca.14519","volume":"7","author":"W Huang","year":"2016","unstructured":"Huang, W. et al. Proteasome inhibitor YSY01A enhances cisplatin cytotoxicity in cisplatin-resistant human ovarian Cancer cells. J. Cancer. 7 (9), 1133\u20131141 (2016).","journal-title":"J. Cancer"},{"issue":"7","key":"76945_CR62","doi-asserted-by":"publisher","first-page":"3754","DOI":"10.1158\/0008-5472.CAN-05-2321","volume":"66","author":"M Bazzaro","year":"2006","unstructured":"Bazzaro, M. et al. Ubiquitin-proteasome system stress sensitizes ovarian cancer to proteasome inhibitor-induced apoptosis. Cancer Res. 66 (7), 3754\u20133763 (2006).","journal-title":"Cancer Res."},{"issue":"3","key":"76945_CR63","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1158\/0008-5472.CAN-07-2580","volume":"68","author":"R Klinck","year":"2008","unstructured":"Klinck, R. et al. Multiple alternative splicing markers for ovarian cancer. Cancer Res. 68 (3), 657\u2013663 (2008).","journal-title":"Cancer Res."},{"issue":"1","key":"76945_CR64","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S0959-437X(00)00154-4","volume":"11","author":"G Pawlak","year":"2001","unstructured":"Pawlak, G. & Helfman, D. M. Cytoskeletal changes in cell transformation and tumorigenesis. Curr. Opin. Genet. Dev. 11 (1), 41\u201347 (2001).","journal-title":"Curr. Opin. Genet. Dev."},{"issue":"Pt 8","key":"76945_CR65","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1242\/jcs.067009","volume":"124","author":"PP Provenzano","year":"2011","unstructured":"Provenzano, P. P. & Keely, P. J. Mechanical signaling through the cytoskeleton regulates cell proliferation by coordinated focal adhesion and rho GTPase signaling. J. Cell. Sci. 124 (Pt 8), 1195\u20131205 (2011).","journal-title":"J. Cell. Sci."},{"issue":"11","key":"76945_CR66","doi-asserted-by":"publisher","first-page":"e8027","DOI":"10.1371\/journal.pone.0008027","volume":"4","author":"DV Ayollo","year":"2009","unstructured":"Ayollo, D. V., Zhitnyak, I. Y., Vasiliev, J. M. & Gloushankova, N. A. Rearrangements of the actin cytoskeleton and e-cadherin-based adherens junctions caused by neoplasic transformation change cell-cell interactions. PLoS One. 4 (11), e8027 (2009).","journal-title":"PLoS One"},{"key":"76945_CR67","doi-asserted-by":"crossref","unstructured":"Luo, X. et al. Identification of a Prognostic Signature for Ovarian Cancer Based on Ubiquitin-Related Genes Suggesting a Potential Role for FBXO9. Biomolecules ; 13(12). (2023).","DOI":"10.3390\/biom13121724"},{"issue":"22","key":"76945_CR68","doi-asserted-by":"publisher","first-page":"12907","DOI":"10.18632\/aging.205210","volume":"15","author":"GQ Song","year":"2023","unstructured":"Song, G. Q. et al. The necroptosis signature and molecular mechanism of lung squamous cell carcinoma. Aging (Albany NY). 15 (22), 12907\u201312926 (2023).","journal-title":"Aging (Albany NY)"},{"issue":"2","key":"76945_CR69","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1002\/JLB.4RI0818-311R","volume":"106","author":"CE Olingy","year":"2019","unstructured":"Olingy, C. E., Dinh, H. Q. & Hedrick, C. C. Monocyte heterogeneity and functions in cancer. J. Leukoc. Biol. 106 (2), 309\u2013322 (2019).","journal-title":"J. Leukoc. Biol."},{"key":"76945_CR70","doi-asserted-by":"crossref","unstructured":"Almeida-Nunes, D. L., Mendes-Frias, A., Silvestre, R., Dinis-Oliveira, R. J. & Ricardo, S. Immune Tumor Microenvironment in Ovarian Cancer Ascites. Int J Mol Sci ; 23(18). (2022).","DOI":"10.3390\/ijms231810692"},{"key":"76945_CR71","doi-asserted-by":"crossref","unstructured":"Nowak, M. & Klink, M. The role of Tumor-Associated macrophages in the Progression and Chemoresistance of Ovarian Cancer. Cells 9(5), 1299 (2020).","DOI":"10.3390\/cells9051299"},{"key":"76945_CR72","doi-asserted-by":"publisher","first-page":"103374","DOI":"10.1016\/j.critrevonc.2021.103374","volume":"163","author":"A Addeo","year":"2021","unstructured":"Addeo, A., Friedlaender, A., Banna, G. L. & Weiss, G. J. TMB or not TMB as a biomarker: that is the question. Crit. Rev. Oncol. Hematol. 163, 103374 (2021).","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"22","key":"76945_CR73","doi-asserted-by":"publisher","first-page":"640","DOI":"10.21037\/atm.2019.10.116","volume":"7","author":"HX Wu","year":"2019","unstructured":"Wu, H. X. et al. Tumor mutational and indel burden: a systematic pan-cancer evaluation as prognostic biomarkers. Ann. Transl Med. 7 (22), 640 (2019).","journal-title":"Ann. Transl Med."},{"issue":"17","key":"76945_CR74","doi-asserted-by":"publisher","first-page":"4685","DOI":"10.1158\/1078-0432.CCR-21-0327","volume":"27","author":"L Marcus","year":"2021","unstructured":"Marcus, L. et al. FDA approval Summary: Pembrolizumab for the treatment of Tumor Mutational Burden-High Solid tumors. Clin. Cancer Res. 27 (17), 4685\u20134689 (2021).","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"76945_CR75","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.ccell.2020.10.001","volume":"39","author":"DL Jardim","year":"2021","unstructured":"Jardim, D. L., Goodman, A., de Melo Gagliato, D. & Kurzrock, R. The challenges of Tumor Mutational Burden as an Immunotherapy Biomarker. Cancer Cell. 39 (2), 154\u2013173 (2021).","journal-title":"Cancer Cell."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-76945-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-76945-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-76945-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T22:03:13Z","timestamp":1730152993000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-76945-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,24]]},"references-count":75,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["76945"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-76945-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,24]]},"assertion":[{"value":"10 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"25239"}}